KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $10.3 million.

  • Nektar Therapeutics' Cost of Revenue fell 650.14% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.5 million, marking a year-over-year increase of 563.8%. This contributed to the annual value of $42.0 million for FY2024, which is 1349.33% up from last year.
  • Per Nektar Therapeutics' latest filing, its Cost of Revenue stood at $10.3 million for Q3 2025, which was down 650.14% from $10.3 million recorded in Q2 2025.
  • Nektar Therapeutics' Cost of Revenue's 5-year high stood at $17.3 million during Q1 2025, with a 5-year trough of $5.0 million in Q3 2022.
  • Over the past 5 years, Nektar Therapeutics' median Cost of Revenue value was $7.7 million (recorded in 2021), while the average stood at $8.6 million.
  • Its Cost of Revenue has fluctuated over the past 5 years, first tumbled by 3328.55% in 2022, then surged by 15002.01% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Cost of Revenue (Quarter) stood at $6.2 million in 2021, then grew by 1.14% to $6.2 million in 2022, then skyrocketed by 69.47% to $10.6 million in 2023, then decreased by 18.54% to $8.6 million in 2024, then grew by 19.66% to $10.3 million in 2025.
  • Its Cost of Revenue was $10.3 million in Q3 2025, compared to $10.3 million in Q2 2025 and $17.3 million in Q1 2025.